JP2020534839A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534839A5 JP2020534839A5 JP2020517553A JP2020517553A JP2020534839A5 JP 2020534839 A5 JP2020534839 A5 JP 2020534839A5 JP 2020517553 A JP2020517553 A JP 2020517553A JP 2020517553 A JP2020517553 A JP 2020517553A JP 2020534839 A5 JP2020534839 A5 JP 2020534839A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- amino acid
- acid sequence
- mutant
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 40
- 238000000034 method Methods 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 27
- 239000000427 antigen Substances 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 14
- 108091008874 T cell receptors Proteins 0.000 claims 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 4
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 4
- 108010063738 Interleukins Proteins 0.000 claims 4
- 102000015696 Interleukins Human genes 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 3
- 108700025694 p53 Genes Proteins 0.000 claims 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 239000013642 negative control Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 101150111660 53 gene Proteins 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000003501 co-culture Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565464P | 2017-09-29 | 2017-09-29 | |
| US62/565,464 | 2017-09-29 | ||
| PCT/US2018/051280 WO2019067242A1 (en) | 2017-09-29 | 2018-09-17 | METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534839A JP2020534839A (ja) | 2020-12-03 |
| JP2020534839A5 true JP2020534839A5 (https=) | 2021-10-28 |
| JP7391015B2 JP7391015B2 (ja) | 2023-12-04 |
Family
ID=63763012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517553A Active JP7391015B2 (ja) | 2017-09-29 | 2018-09-17 | Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200316121A1 (https=) |
| EP (2) | EP4495133A3 (https=) |
| JP (1) | JP7391015B2 (https=) |
| KR (1) | KR102809909B1 (https=) |
| CN (1) | CN111344394A (https=) |
| AU (1) | AU2018342245B2 (https=) |
| CA (1) | CA3080274A1 (https=) |
| IL (1) | IL273516B2 (https=) |
| SG (1) | SG11202002635RA (https=) |
| WO (1) | WO2019067242A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240007775A (ko) | 2016-12-08 | 2024-01-16 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
| DE102016123847B3 (de) * | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| AU2018269370B2 (en) | 2017-05-16 | 2025-06-05 | The Johns Hopkins University | Manabodies and methods of using |
| TW202525841A (zh) * | 2019-06-27 | 2025-07-01 | 美國衛生與公眾服務部 | 識別p53中之r175h或y220c突變之t細胞受體 |
| CN112390875B (zh) * | 2019-08-16 | 2023-01-24 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的高亲和力t细胞受体 |
| WO2021127184A1 (en) * | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| BR112022011795A2 (pt) | 2019-12-20 | 2022-08-30 | Instil Bio Uk Ltd | Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| TWI900647B (zh) * | 2020-09-04 | 2025-10-11 | 美國衛生與公眾服務部 | 識別p53中r273c或y220c突變的t細胞受體 |
| CN112301088B (zh) * | 2020-10-21 | 2022-12-13 | 杭州纽安津生物科技有限公司 | 一种筛选新生抗原或新生抗原编码序列的方法 |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| JP2024509472A (ja) * | 2021-03-08 | 2024-03-01 | 大鵬薬品工業株式会社 | Ｆｇｆｒ２及び癌ドライバー遺伝子に遺伝子変化が同時発生する患者におけるがんの治療 |
| EP4314027A2 (en) * | 2021-03-31 | 2024-02-07 | The Johns Hopkins University | Methods and materials for targeting tumor antigens |
| JP2024517884A (ja) * | 2021-05-07 | 2024-04-23 | アメリカ合衆国 | ｐ５３におけるＣ１３５Ｙ、Ｒ１７５Ｈ又はＭ２３７Ｉ変異を認識するＴ細胞受容体 |
| JP2024525727A (ja) | 2021-07-14 | 2024-07-12 | ２セブンティ バイオ インコーポレイテッド | 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体 |
| JP2024540197A (ja) * | 2021-10-29 | 2024-10-31 | ホウ，ヤフェイ | Ｐ５３におけるｒ１７５ｈ変異を認識するｔ細胞受容体およびその用途 |
| CA3255500A1 (en) | 2022-04-08 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | MULTI-PART RECEIVERS AND SIGNALING COMPLEXES |
| WO2024131372A1 (zh) * | 2022-12-23 | 2024-06-27 | 上海市第一人民医院 | 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用 |
| KR20260028688A (ko) * | 2023-05-25 | 2026-03-04 | 엘리시오 테라퓨틱스, 인크. | P53 펩티드 양친매체를 함유하는 조성물 및 이의 이용 방법 |
| CN116970058B (zh) * | 2023-09-22 | 2023-12-15 | 成都朗谷生物科技股份有限公司 | 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用 |
| WO2025060149A1 (zh) * | 2023-09-22 | 2025-03-27 | 上海市第一人民医院 | 一种分离的tcr及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2139012T3 (es) * | 1992-05-26 | 2000-02-01 | Univ Leiden | Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana. |
| JPH0959175A (ja) * | 1995-06-12 | 1997-03-04 | Meiji Milk Prod Co Ltd | 抗腫瘍免疫活性化剤 |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| GB2440736A (en) * | 2006-08-10 | 2008-02-13 | Medical Res Council | Crystals of mutant p53 polypeptidtes |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| JP6599450B2 (ja) | 2014-10-02 | 2019-10-30 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 |
| AU2014407539B2 (en) | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
| US20170333480A1 (en) * | 2014-11-05 | 2017-11-23 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| CN118994363A (zh) * | 2014-11-26 | 2024-11-22 | 美国卫生和人力服务部 | 抗突变的kras的t细胞受体 |
| WO2019067243A1 (en) * | 2017-09-29 | 2019-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T CELL RECEPTORS RECOGNIZING P53 MUTE |
-
2018
- 2018-09-17 SG SG11202002635RA patent/SG11202002635RA/en unknown
- 2018-09-17 JP JP2020517553A patent/JP7391015B2/ja active Active
- 2018-09-17 EP EP24215129.8A patent/EP4495133A3/en active Pending
- 2018-09-17 IL IL273516A patent/IL273516B2/en unknown
- 2018-09-17 WO PCT/US2018/051280 patent/WO2019067242A1/en not_active Ceased
- 2018-09-17 KR KR1020207012343A patent/KR102809909B1/ko active Active
- 2018-09-17 CA CA3080274A patent/CA3080274A1/en active Pending
- 2018-09-17 AU AU2018342245A patent/AU2018342245B2/en active Active
- 2018-09-17 CN CN201880063656.4A patent/CN111344394A/zh active Pending
- 2018-09-17 US US16/650,696 patent/US20200316121A1/en active Pending
- 2018-09-17 EP EP18782605.2A patent/EP3688142B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534839A5 (https=) | ||
| IL273516B2 (en) | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation | |
| JP2017531640A5 (https=) | ||
| Alizadeh et al. | IFNγ is critical for CAR T cell–mediated myeloid activation and induction of endogenous immunity | |
| AU2018262698B2 (en) | Expansion of gamma delta T cells, compositions, and methods of use thereof | |
| KR102821381B1 (ko) | 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도 | |
| CN110612446B (zh) | 分离新抗原-特异性t细胞受体序列的方法 | |
| CN104159917A (zh) | 使用icos基cars增强抗肿瘤活性和car持久性 | |
| CA2791975A1 (en) | Icos critically regulates the expansion and function of inflammatory human th17 cells | |
| JP2024527559A5 (https=) | ||
| JP2023504042A5 (https=) | ||
| CN113101363B (zh) | 一种环状rna疫苗及其应用 | |
| Song et al. | Targeting cytokine signals to enhance γδT cell-based cancer immunotherapy | |
| CN114786779A (zh) | 用于t细胞受体鉴定的组合物和方法 | |
| CN117580946A (zh) | 用于产生抗原特异性t细胞的方法 | |
| US20240216426A1 (en) | Recombinant antigen presenting cells | |
| TW202405166A (zh) | 用於活化免疫細胞之組合物及方法 | |
| Dickerson et al. | Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours | |
| US20210113617A1 (en) | Methods and compositions for th9 cell mediated cancer treatment | |
| JP7793523B2 (ja) | 人工多能性幹細胞を用いたｔ細胞集団の製造方法 | |
| WO2021092719A1 (zh) | 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白 | |
| CN117242090A (zh) | CAR T细胞疗法和IFNγ | |
| An et al. | Advances in IL-2 family cytokine-based cancer therapies: overcoming challenges through molecular engineering and delivery strategies | |
| HK40105281A (zh) | CAR T细胞疗法和IFNγ | |
| US20250073268A1 (en) | Chimeric cd40 polypeptides and methods of use in immunotherapy |